Hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 10, 2013, Pages 1227-1233

  Deeg, H Joachim ^a   De Lima, Marcos ^b  

^a USA   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CYCLOSPORIN; FLUDARABINE; GLUCOCORTICOID; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE TOXICITY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; DRUG TOLERANCE; GERIATRIC CARE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LONG TERM CARE; LONG TERM SURVIVAL; MORTALITY; MYELODYSPLASTIC SYNDROME; RELAPSE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887238674     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0145     Document Type: Article

References (60)

1. Hamblin TJ. Epidemiology of the myelodysplastic syndromes. In: Bennett JM, ed. The Myelodysplastic Syndromes: Pathobiology and Clinical Management. New York, NY: Marcel Dekker, Inc.; 2002: 15-27.
2. De Roos A.J., Deeg HJ, Onstad L, et al Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006. Am J Hematol 2010; 85: 765-770.
3. Rollison DE, Howlader N, Smith M.T., et al Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112: 45-52.
4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
5. Silverman LR, Demakos EP, Peterson B.L., et al Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440.
6. List A, Dewald G, Bennett J., et al Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
7. de Lima M., Couriel D, Thall P F, et al Once-daily intravenous buslfan and fludarabine: clinical and pharmacokinetic results of a myeloabltive, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864.
8. Karoopongse E, Deeg HJ Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade. Expert Rev Clin Immunol 2012; 8: 373-381.
9. Sorror ML, Sandmaier BM, Storer B.E., et al Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246-4254.
10. Samuelson S, Sandmaier BM, Heslop H.E., et al Allogeneic haematopoeietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol 2011; 153: 76-82.
11. Martino R, de Wreede L, Fiocco M, et al Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow Transplant 2013; 48: 761-770.
12. Sorror ML, Giralt S, Sandmaier B.M., et al Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110: 4608-4613.
13. Sorror ML, Sandmaier BM, Storer B.E., et al Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011; 306: 1874-1883.
14. Parimon T, Au DH, Martin P.J., Chien JW A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144: 407-414.
15. Eissa H, Gooley TA, Sorror M.L., et al Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant 2011; 17: 908-915.
16. Verstovsek S, Mesa RA, Gotlib J, et al A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
17. Armand P, Kim HT, Cutler C.S., et al Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-4588.
18. Meyer SC, O'Meara A, Buser AS, et al Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19: 440-444.
19. Platzbecker U, Bornhäuser M, Germing U., et al Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 2008; 14: 1217-1225.
20. Greenberg PL, Tuechler H, Schanz J., et al Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
21. Kantarjian H, O'Brien S, Ravandi F, et al Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008; 113: 1351-1361.
22. Cazzola M, Della Porta MG, Travaglino E, Malcovati L. Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol 2011; 38: 627-634.
23. Valcarcel D, Adema V, Sole F., et al Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol 2013; 31: 916-922.
24. Deeg HJ, Scott BL, Fang M, et al Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012; 120: 1398-1408.
25. Anderson JE, Appelbaum FR, Schoch G, et al Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220-226.
26. Gerds AT, Gooley TA, Estey E.H., et al Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012; 18: 1211-1218.
27. Field T, Perkins J, Huang Y., et al 5-azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010; 45: 255-260.
28. De Padua S.L., de Lima M, Kantarjian H, et al Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009; 43: 839-843.
29. Lubbert M, Bertz H, Ruter B., et al Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009; 44: 585-588.
30. Estey EH, Kantarjian HM, O'Brien S, et al High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther 1995; 1: 21-28.
31. Platzbecker U, Schetelig J, Finke J., et al Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant 2012; 18: 1415-1421.
32. Koreth J, Pidala J, Perez W.S., et al The role of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in older patients with de-novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 2013; 31: 2662-2670.
33. Li X, Marcondes AM, Gooley T.A., Deeg HJ The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. Blood 2010; 116: 2304-2314.
34. Bartlett NL, Petroni GR, Parker B.A., et al Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. Cancer 2001; 92: 207-217.
35. Walter MJ, Shen D, Ding L., et al Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090-1098.
36. Malcovati L, Della Porta MG, Strupp C, et al Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011; 96: 1433-1440.
37. Prébet T., Gore SD, Esterni B, et al Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29: 3322-3327.
38. Flowers MED, Vogelsang GB Clinical manifestations and natural history. In: Vogelsang GB, Pavletic SZ, eds. Chronic Graft Versus Host Disease: Interdisciplinary Management. New York, NY: Cambridge University Press; 2009: 56-69.
39. Inamoto Y, Flowers ME Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol 2011; 18: 414-420.
40. O'Donnell P V, Pedersen TL, Confer DL, et al. Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. Blood 2010; 115: 5097-5101.
41. Alousi AM, Le-Rademacher J, Saliba R.M., et al Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood 2013; 121: 2567-2573.
42. Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 2011; 117: 2332-2339.
43. Delaney C, Ratajczak MZ, Laughlin MJ Strategies to enhance umbilical cord blood stem cell engraftment in adult patients. Expert Rev Hematol 2010; 3: 273-283.
44. Sato A, Ooi J, Takahashi S., et al Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. Bone Marrow Transplant 2011; 46: 257-261.
45. Kasamon YL, Luznik L, Leffell M.S., et al Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010; 16: 482-489.
46. Luznik L, O'Donnell P V, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-650.
47. O'Donnell P V, Harrington E, Gooley TA, et al. Cyclophosphamide-induced tolerance following bone marrow transplantation from haploidentical donors. Haematologica 2010; 95 (Extra 1):266-271.
48. Slavin S, Nagler A, Naparstek E., et al Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
49. de Lima M., Shahjahan M, Alamo J., et al Allogeneic hematopoietic stem cell transplantation (HSCT) for patients aged 65 years or older with AML and MDS [abstract]. Blood 2004; 104 (Part 1):632a.
50. Kroger N, Bornhauser M, Ehninger G., et al Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336-342.
51. Shimoni A, Hardan I, Shem-Tov N, et al Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up. Leukemia 2010; 24: 1050-1052.
52. Laport GG, Sandmaier BM, Storer B.E., et al Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008; 14: 246-255.
53. Martino R, Parody R, Fukuda T., et al Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928-2936.
54. Mura M, Belmonte G, Fanti S., et al Inflammatory activity is still present in the advanced stages of idiopathic pulmonary fibrosis. Respirology 2005; 10: 609-614.
55. de Lima M., Giralt S, Thall P.F., et al Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010; 116: 5420-5431.
56. Warren EH, Fujii N, Akatsuka Y., et al Therapy of relapsed leukemia after allogeneic hematopoietiic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010; 115: 3869-3878.
57. Mielcarek M, Martin PJ, Leisenring W, et al Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
58. Stewart BL, Storer B, Storek J., et al Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004; 104: 3501-3506.
59. Baker KS, Ness KK, Steinberger J, et al Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 2007; 109: 1765-1772.
60. Boeckh M, Marr KA Infection in hematopoietic stem cell transplantation. In: Rubin RH, Young LS, eds. Clinical Approach to Infection in the Compromised Host. New York, NY: Kluwer Academic/Plenum Publishers; 2002: 527-571.